The American Medical Association (AMA) stated in its June 2001 "Summaries and Recommendations of Council on Scientific Affairs Reports" :

“The AMA calls for further adequate and well-controlled studies of marijuana and related cannabinoids in patients who have serious conditions for which preclinical, anecdotal, or controlled evidence suggests possible efficacy and the application of such results to the understanding and treatment of disease.

The AMA recommends that marijuana be retained in Schedule I of the Controlled Substances Act pending the outcome of such studies.”

June 2001